PAKs, RAC/CDC42 (p21)-activated Kinases: Towards the Cure of Cancer and Other PAK-dependent Diseases
During the last decade, a series of PAK1 blockers were developed or identified, including synthetic compounds as well as a variety of natural products (antibiotics).
Among them the natural ring peptide FK228 is the most potent PAK1 blocker.
Developed by Fujisawa Pharmaceuticals in Japan, it is a potent HDAC (histone deacetylase)
inhibitor [15] that eventually blocks both upstream and downstream action of
PAK1 with the IC below 1 nM [12]. However, since FK228 is unable to pass the blood–brain barrier (BBB), it may be ineffective for brain tumors such as gliomas
and tumors associated with NF and tuberous sclerosis (TSC), whose growth also requires PAK1. 50
This book covers a variety of cutting-edge basic and clinical PAK research ranging from laboratory benches to hospital beds.
The goal of this book is to inspire not only biomedical research scientists and university students, but also a variety of patients who suffer from PAK-dependent diseases and clinical doctors who try to cure or delay these PAK-dependent diseases.
English -- 2013 -- ISBN: 0124071988 -- 276 pages -- PDF -- 7,5 MB
Download
*
During the last decade, a series of PAK1 blockers were developed or identified, including synthetic compounds as well as a variety of natural products (antibiotics).
Among them the natural ring peptide FK228 is the most potent PAK1 blocker.
Developed by Fujisawa Pharmaceuticals in Japan, it is a potent HDAC (histone deacetylase)
inhibitor [15] that eventually blocks both upstream and downstream action of
PAK1 with the IC below 1 nM [12]. However, since FK228 is unable to pass the blood–brain barrier (BBB), it may be ineffective for brain tumors such as gliomas
and tumors associated with NF and tuberous sclerosis (TSC), whose growth also requires PAK1. 50
This book covers a variety of cutting-edge basic and clinical PAK research ranging from laboratory benches to hospital beds.
The goal of this book is to inspire not only biomedical research scientists and university students, but also a variety of patients who suffer from PAK-dependent diseases and clinical doctors who try to cure or delay these PAK-dependent diseases.
English -- 2013 -- ISBN: 0124071988 -- 276 pages -- PDF -- 7,5 MB
Download
*